Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 19/2003

01-10-2003 | Adis Drug Profile

Telmisartan/Hydrochlorothiazide

In the Treatment of Essential Hypertension

Authors: Caroline Fenton, Gillian M. Keating, Lesley J. Scott

Published in: Drugs | Issue 19/2003

Login to get access

Abstract

  • ▴ Oral telmisartan/hydrochlorothiazide (HCTZ) combines two antihypertensive agents, a selective angiotensin II receptor antagonist with a long half-life and once-daily administration, and a thiazide diuretic.
  • ▴ In two large, 8-week, double-blind trials, patients with hypertension unresponsive to monotherapy who received combined telmisartan/HCTZ 80/12.5 or 40/12.5 mg/day, achieved significantly larger reductions in diastolic and systolic blood pressure (BP), than recipients of continued telmisartan monotherapy (p < 0.05 for all). Compliance with telmisartan/HCTZ 80/12.5 mg/day was 98.9%.
  • ▴ In patients with hypertension, telmisartan/HCTZ resulted in similar BP reductions to oral enalapril/ HCTZ and atenolol/HCTZ in 26-week double-blind trials and greater reductions than oral losartan/ HCTZ 50/12.5 mg/day in a 6-week randomised open-label trial (p < 0.001).
  • ▴ Up to one-third of patients with hypertension initially responsive to telmisartan 40 or 80 mg/day in a 4-year study required the eventual addition of HCTZ 12.5 or 25 mg/day and/or another agent to maintain BP control. BP was controlled in about 75% of these by adding only HCTZ.
  • ▴ In clinical trials of up to 4 years, including elderly patients, telmisartan/HCTZ had similar tolerability to placebo, with few reports of hypokalaemia. Most adverse events were mild to moderate.
Footnotes
1
Use of tradenames is for product identification purposes only and does not imply endorsement.
 
Literature
1.
McGill JB, Reilly PA. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther 2001 Jun; 23(6): 833–50PubMedCrossRef
2.
Freytag F, Holwerda NJ, Karlberg BE, et al. Long-term exposure to telmisartan as monotherapy or combination therapy: efficacy and safety. Blood Press 2002; 11(3): 173–81PubMedCrossRef
3.
Lacourcière Y, Martin K. Comparison of a fixed-dose combination of 40 mg telmisartan plus 12.5 mg hydrochlorothiazide with 40 mg telmisartan in the control of mild to moderate hypertension. Am J Ther 2002 Mar–Apr; 9(2): 111–7PubMedCrossRef
4.
Lacourcière Y. A new fixed-dose combination for added blood pressure control: telmisartan plus hydrochlorothiazide. J Int Med Res 2002 Jul–Aug; 30(4): 366–79PubMed
5.
Lacourcière Y, Tytus R, O’Keefe D, et al. Efficacy and tolerability of a fixed-dose combination of telmisartan plus hydrochlorothiazide in patients uncontrolled with telmisartan mono-therapy. J Hum Hypertens 2001 Nov; 15(11): 763–70PubMedCrossRef
6.
Sharpe M, Jarvis B, Goa KL. Telmisartan: a review of its use in hypertension. Drugs 2001; 61(10): 1501–29PubMedCrossRef
7.
Maillard MP, Perregaux C, Centeno C, et al. In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist. J Pharmacol Exp Ther 2002 Sep; 302(3): 1089–95PubMedCrossRef
8.
Balt JC, Mathy MJ, Nap A, et al. Effect of the AT1-receptor antagonists losartan, irbesartan, and telmisartan on angiotensin II-induced facilitation of sympathetic neurotransmission in the rat mesenteric artery. J Cardiovasc Pharmacol 2001 Jul; 38(1): 141–8PubMedCrossRef
9.
Stangier J, Su CA, van Heiningen PN, et al. Inhibitory effect of telmisartan on the blood pressure response to angiotensin II challenge. J Cardiovasc Pharmacol 2001 Nov; 38(5): 672–85PubMedCrossRef
10.
Forclaz A, Maillard M, Nussberger J, et al. Angiotensin II receptor blockade: is there truly a benefit of adding an ACE inhibitor? Hypertension 2003 Jan; 41: 31–6PubMedCrossRef
11.
Burgess ED, Buckley S. Acute natriuretic effect of telmisartan in hypertensive patients [abstract no. 1025]. Am J Hypertens 2000 Apr; 13 (Pt 2): 183
12.
Burgess ED, Buckley S. Long-term effect of telmisartan on sodium excretion in hypertensive patients [abstract no. 58]. Can J Cardiol 2000 Sep; 16 Suppl. F: 106
13.
Weber M. The telmisartan programme of research to show telmisartan end-organ protection (PROTECTION) programme. J Hypertens 2003; 21 Suppl. 6: S37–46
14.
Beermann B, Groschinsky-Grind M. Pharmacokinetics of hydrochlorothiazide in man. Eur J Clin Pharmacol 1977 Dec 2; 12(4): 297–303PubMedCrossRef
15.
Ripley E, King K, Sica DA. Racial differences in response to acute dosing with hydrochlorothiazide. Am J Hypertens 2000; 13(2): 157–64PubMedCrossRef
16.
van Brummelen P, Man in ’t Veld AJ, Schalekamp MADH. Hemodynamic changes during long-term thiazide treatment of essential hypertension in responders and non-responders. Clin Pharmacol Ther 1980 Mar; 27(3): 328–36PubMedCrossRef
17.
Pickkers P, Hughes AD, Russel FGM, et al. Thiazide-induced vasodilation in humans is mediated by potassium channel activation. Hypertension 1998 Dec; 32: 1071–6PubMedCrossRef
18.
Pickkers P, Garcha RS, Schachter M, et al. Inhibition of carbonic anhydrase accounts for the direct vascular effect of hydrochlorothiazide. Hypertension 1999 Apr; 33: 1043–8PubMedCrossRef
19.
Wienen W, Schierok HJ. Effects of telmisartan, hydrochlorothiazide and their combination on blood pressure and renal excretory parameters in spontaneously hypertensive rats. J Renin Angiotensin Aldosterone Syst 2001 Jun; 2(2): 123–8PubMed
20.
Yong CL, Dias VC, Stangier J. Multiple-dose pharmacokinetics of telmisartan and of hydrochlorothiazide following concurrent administration in healthy subjects. J Clin Pharmacol 2000 Dec; 40 (12 Pt 1): 1323–30
21.
Stangier J, Schmid J, Turck D, et al. Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers. J Clin Pharmacol 2000 Dec; 40 Pt 1: 1312–22
22.
Stangier J, Su CAPF, Roth W. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res 2000 Jul–Aug; 28: 149–67PubMed
23.
Neutel JM, Smith DHG, Telmisartan US Study Group. Dose response and antihypertensive efficacy of the AT1receptor antagonist telmisartan in patients with mild to moderate hypertension. Adv Ther 1998 Jul–Aug; 15: 206–17
24.
Stangier J, Su C-APF, Schondorfer G, et al. Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers. J Clin Pharmacol 2000 Dec; 40 Pt 1: 1355–64PubMed
25.
Stangier J, Heinzel G, Su C-A, et al. Clinical pharmacokinetics of telmisartan [abstract no. P.49]. J Hum Hypertens 1999 May; 13 Suppl. 3: 13
26.
Patel RB, Patel UR, Rogge MC, et al. Bioavailability of hydrochlorothiazide from tablets and suspensions. J Pharm Sci 1984 Mar; 73(3): 359–61PubMedCrossRef
27.
Barbhaiya RH, Craig WA, Corrick-West HP, et al. Pharmacokinetics of hydrochlorothiazide in fasted and nonfasted subjects: a comparison of plasma level and urinary excretion methods. J Pharm Sci 1982 Feb; 71(2): 245–8PubMedCrossRef
28.
Chen TM, Chiou WL. Large differences in the biological half-life and volume of distribution of hydrochlorothiazide in normal subjects from eleven studies. Correlation with their last blood sampling times. Int J Clin Pharmacol Ther Toxicol 1992 Jan; 30(1): 34–7PubMed
29.
Niemeyer C, Hasenfuss G, Wais U, et al. Pharmacokinetics of hydrochlorothiazide in relation to renal function. Eur J Clin Pharmacol 1983; 24(5): 661–5PubMedCrossRef
30.
Boehringer Ingelheim. Telmisartan prescribing information. 2000
31.
Stangier J, Su C-APF, Brickl R, et al. Pharmacokinetics of single-dose telmisartan 120 mg given during and between hemodialysis in subjects with severe renal insufficiency: comparison with healthy volunteers. J Clin Pharmacol 2000 Dec; 40 Pt 1: 1365–72PubMed
32.
Hannedouche T, Chanard J, Baumelou B. Evaluation of the safety and efficacy of telmisartan and enalapril, with the potential addition of frusemide, in moderate-renal failure patients with mild-to-moderate hypertension. J Renin Angiotensin Aldosterone Syst 2001 Dec; 2(4): 246–54PubMedCrossRef
33.
Beermann B, Groschinsky-Grind M. Pharmacokinetics of hydrochlorothiazide in patients with congestive heart failure. Br J Clin Pharmacol 1979 Jun; 7(6): 579–83PubMedCrossRef
34.
Lacourcière Y, Gil-Extremera B, Mueller O, et al. Efficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ compared with losartan plus HCTZ in patients with essential hypertension. Int J Clin Pract 2003 May; 57: 237–79
35.
Neutel JM, Klein C, Meinicke TW, et al. Long-term efficacy and tolerability of telmisartan as monotherapy and in combination with other antihypertensive medications. Blood Press 2002; 11(5): 302–9PubMedCrossRef
36.
Freytag F, Schelling A, Meinicke T, et al. Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild to moderate hypertension: a randomized, multicenter study. Clin Ther 2001 Jan; 23(1): 108–23PubMedCrossRef
37.
Karlberg BE, Lins L-E, Hermansson K. Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. J Hypertens 1999; 17(2): 293–302PubMedCrossRef
38.
McGill JB, Reilly PA. Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertension. Clin Cardiol 2001 Jan; 24(1): 66–72PubMedCrossRef
39.
40.
Lacourcière Y, Poirier L, Extremera BG, et al. Telmisartan in combination with hydrochlorothiazide or losartan in combination with hydrochlorothiazide; ABPM assessment of blood pressure lowering. Am J Hypertens 2002 Apr; 15 (Pt 2): 113
41.
Mancia G. Tolerability and safety of telmisartan as monotherapy or combined with hydrochlorothiazide compared with placebo [abstract no. R194]. J Hypertens 2002 Jun; 20 (4 Suppl.): 377
42.
European Agency for the Evaluation of Medicinal Products. Summary of product characteristics for telmisartan/hydrochlorothiazide [online]. Available from URL: http://​www.​emea.​eu.​int [Accessed 2003 May 20]
Metadata
Title
Telmisartan/Hydrochlorothiazide
In the Treatment of Essential Hypertension
Authors
Caroline Fenton
Gillian M. Keating
Lesley J. Scott
Publication date
01-10-2003
Publisher
Springer International Publishing
Published in
Drugs / Issue 19/2003
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200363190-00006

Other articles of this Issue 19/2003

Drugs 19/2003 Go to the issue

Adis Drug Evaluation

Measles, Mumps, Rubella Vaccine (Priorix™ GSK-MMR)

Leading Article

Therapy for Chronic Obstructive Pulmonary Disease in the 21st Century

Current Opinion

Aldosterone Receptor Antagonists for Hypertension

Adis Drug Evaluation

Oxaliplatin

Adis Drug Evaluation

Lamotrigine

Adis Drug Profile

Transdermal Buprenorphine